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Abstract Peripartum cardiomyopathy is a rare but potentially
life-threatening form of heart failure affecting women late in
pregnancy or in the first months after delivery. Peripartum
cardiomyopathy is difficult to diagnose and its onset and
progression are variable between individuals. The pathophys-
iology remains poorly understood, hence treatment options
are limited and possibly harmful to the foetus. Furthermore,
geographical incidence varies greatly and little is known about
the incidence in Western countries. To gain further under-
standing of the pathophysiology and incidence of peripartum
cardiomyopathy, the European Society of Cardiology initiated
a study group to implement a registry. This review provides an
overview of current insights into peripartum cardiomyopathy,
highlights the need for such a registry and provides informa-
tion about this Euro Observational Research Program.
pregnancy or in the first months after delivery. Little
is known about the prevalence, aetiology and potential
therapeutic options. To gain further understanding of the
prevalence and pathophysiology of peripartum cardio-
myopathy, the European Society of Cardiology (ESC)
initiated a study group to implement a registry. This review
provides an overview of current insights into peripartum
cardiomyopathy, highlights the need for such a registry
and provides information about this Euro Observational
Research Program.
Clinical presentation
The incidence of peripartum cardiomyopathy varies geo-
graphically, for instance from 1:2300 to 1:4000 in the USA
and is as high as 1:300 in Haiti [1, 2]. However, the incidence
of peripartum cardiomyopathy in Europe remains unknown. It
is characterised by left ventricular dysfunction, manifesting
predominantly in the first months postpartum. Peripartum
cardiomyopathy is primarily a clinical diagnosis of exclusion.
The definition of peripartum cardiomyopathy has changed
over the years, but recently the ESC Working Group on
peripartum cardiomyopathy has accepted the following defi-
nition: ‘an idiopathic cardiomyopathy presenting with heart
failure secondary to left ventricular systolic dysfunction to-
wards the end of pregnancy or in the months following deliv-
ery, where no other cause of heart failure is found’ [2].
Multiparity, multiple births, older maternal age and
prolonged tocolytic therapy are factors found to predispose
to the development of peripartum cardiomyopathy. Other
suggested risk factors are African origin, family history of
cardiomyopathy and pregnancy-induced hypertension [1, 3].
In addition, a recent literature review showed a clear associa-
tion between the incidence of preeclampsia and peripartum
cardiomyopathy [4].
Clinical features consist of dyspnoea on exertion, orthopnoea
and peripheral oedema. However, an underlying cause such as
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Introduction
Peripartum cardiomyopathy is a rare but potentially life-
threatening form of heart failure affecting women late in
ischaemic, valvular or detectable inherited heart disease should
not be present.Mild symptoms such as fatigue, palpitations, and
abdominal discomfort can be easily misinterpreted as usual
postpartum symptoms and associated with sleep deprivation
and may delay early diagnosis. Subsequently, patients are often
already in New York Heart Association (NYHA) functional
class III-IVat first presentation [2].
Electrocardiography (ECG) can show signs of left ventric-
ular hypertrophy with repolarisation abnormalities or other
nonspecific signs, but the ECG will hardly ever be normal.
In total, 20 % of patients experience non-sustained ventricular
arrhythmias [1]. No information is reported on the incidence
of sustained ventricular tachycardias. Left ventricular dys-
function is part of the diagnosis, while left ventricular dimen-
sions can be normal in patients with dilated cardiomyopathy.
Unfortunately, there is not yet a reliable laboratory test that can
confirm the diagnosis. B-type natriuretic peptide can be used,
but does not distinguish between different causes of heart
failure. Preliminary results revealed microRNA-146a
(miR-146a) as a potential biomarker for clinical use, yet to
be confirmed in prospective studies [1].
Pathogenesis of peripartum cardiomyopathy
The underlying molecular mechanisms of peripartum cardio-
myopathy remain poorly understood. However, serum
markers of apoptosis and inflammation are significantly in-
creased, indicating an impaired adaptive response to the phys-
iological stresses on the heart during pregnancy [3]. Cardiac
stress during pregnancy is mainly due to hormones, oxidative
stress and volume overload. Regarding the last-mentioned
factor, the Janus kinase (JAK)/signal transducers and activa-
tors of transcription (STAT) signalling pathway responds al-
most instantly to stretching neonatal rat and murine
cardiomyocytes [5]. STAT3 activation is essential for
cardioprotective effects; it leads to induction of the reactive
oxygen species (ROS) scavenging enzyme manganese super-
oxide dismutase (MnSOD) [5].
The role of STAT3 in peripartum cardiomyopathy was
discovered in 2007. STAT3 conditional knockout mice devel-
oped peripartum cardiomyopathy in a dose-dependent manner
(conditional knockout heterozygotes). It was observed that
during pregnancy MnSOD levels were increased compared
with nulliparous controls, whereas pregnant STAT3 condition-
al knockout mice showed reduced MnSOD levels. As a con-
sequence, increased ROS levels were found in pregnant STAT
conditional knockout mice versus pregnant controls. It was
shown that STAT3 can be activated by various signals, includ-
ing prolactin [6]. Blood levels of the nursing hormone prolac-
tin are substantially increased during pregnancy. Full-length
prolactin has proangiogenic effects, whereas the 16 kDa
cleaved form elicits antiangiogenic effects. It was determined
that cathepsin D is the major prolactin cleaving enzyme in
peripartum cardiomyopathy [7]. Furthermore, oxidative stress
was found to induce cathepsin D [8]. It is therefore believed
that STAT3 deficiency causes a decreased antioxidative
activity within cardiomyocytes, leading to increased levels
of ROS that in turn activate cathepsin D production. High
serum levels of prolactin during pregnancy combined with
increased cathepsin D production will therefore result in
elevated levels of 16 kDa prolactin leading to cell death and
reduced angiogenesis.
Patten et al. provided further evidence for an imbalance
between proangiogenic and antiangiogenic factors in peri-
partum cardiomyopathy. They have also observed that in-
sufficient angiogenesis during pregnancy leads to peripar-
tum cardiomyopathy development [9]. Like STAT3, PGC-
1α is a gene that promotes the expression of MnSOD, but
unlike STAT3, it also induces the synthesis of vascular
endothelial growth factor (VEGF). Thus, in pregnant
PGC-1α knockout mice, the 16 kDa prolactin-induced
antiangiogenic effect and the inhibition of proangiogenic
factors act together towards the development of a very
severe form of peripartum cardiomyopathy. They found
that PGC-1α knockout mice invariably developed peri-
partum cardiomyopathy. Deficiency of the major angiogenic
mediator PGC-1α in heart leads to decreased secretion of
angiogenic factors such as VEGF, thus inhibiting angiogene-
sis. In late pregnancy, secretion of soluble Flt1 (sFlt1) is
increased, which binds and neutralises soluble VEGF [9].
Proangiogenic therapies (i.e. VEGF injections) were found
to rescue PGC-1α knockout phenotypes [9]. The observation
that women with pre-eclampsia are more frequently affected
by peripartum cardiomyopathy supports a role of oxidative
stress in the pathogenesis of peripartum cardiomyopathy [9].
In line with these findings, Halkein et al. have found miR-
146a to be the link between angiogenic imbalance and cardio-
myocyte dysfunction [10]. When endothelial cells were incu-
bated with 16 kDa prolactin, miR-146a levels increased, which
resulted in reduced angiogenesis. Subsequently exosomal trans-
fer of miR146-a to cardiomyocytes reduced metabolism.
Blocking miR-146a with a specific antagomir causes the atten-
uation of peripartum cardiomyopathy clinical features in
STAT3 conditional knockout mice, without affecting full-
length prolactin-dependent milk production functions [10].
Furthermore, in patients with peripartum cardiomyopathy
miR-146a levels were increased even compared with patients
with dilated cardiomyopathy. Taking these results together, it
appears that reduced angiogenesis at least partially explains the
development of peripartum cardiomyopathy and that miR-146a
might be a useful biomarker in the diagnosis. Further work is
needed to investigate whether this miRNA can serve as a
therapeutic target. Figure 1 provides a summary of the patho-
physiological mechanisms underlying peripartum cardiomyop-
athy in mice, which remain to be confirmed in humans.
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Genetic influences
Classified in 2008 by the ESC as a nonfamilial, nongenetic
form of dilated cardiomyopathy associated with pregnancy
[11], in recent years a growing body of evidence suggests that
part of peripartum cardiomyopathy has a genetic basis. Two
Western studies and one South African case series showed the
occurrence of peripartum cardiomyopathy cases in familial
dilated cardiomyopathy [12]. Accordingly, a positive family
history of cardiomyopathy was seen in 16.5 % (19/115) of
peripartum cardiomyopathy cases in a German peripartum
cardiomyopathy cohort. Recently, more extensive genetic
analysis in families with both dilated cardiomyopathy and
peripartum cardiomyopathy from various parts of the world
revealed a high yield of mutations in cardiomyopathy-related
genes, especially in TTN, the gene encoding for titin.
Pathogenic mutations were found in 4/18 families (22 %),
and mutations that may be pathogenic were found in another
6/18 families (33 %). The majority of identified (likely) path-
ogenic mutations (7/10) were in the TTN gene. Measurements
of passive force in single cardiomyocytes and titin isoform
composition supported the pathogenicity of one of the likely
pathogenic TTN mutations [13]. The mechanisms underlying
the onset of peripartum cardiomyopathy remain unclear, but
certainly genetics is part of a complex interplay of different
factors. Most probably cardiomyopathy-related genes are not
exclusively involved. Moreover, a small genome-wide asso-
ciation study on 41 American peripartum cardiomyopathy
samples showed an association with rs258415, in locus 12p11.22
close to the ParaThyroid Hormone-Like Hormone (PTHLH) gene
[14]. How these findings might functionally link to
peripartum cardiomyopathy is still unclear. However, the geo-
graphical variability of peripartum cardiomyopathy incidence
suggests that genetics plays an important role in peripartum
cardiomyopathy onset.
So far, small patient groups and techniques with limited
throughput have been evident restrictions in genetic studies.
New genomic techniques, such as next-generation sequenc-
ing, now make it possible to analyse larger numbers of genes,
even the entire exome or genome, quickly and at reasonable
costs. It would be most interesting to perform extensive ge-
netic studies on larger numbers of peripartum cardiomyopathy
patients from several parts of the world, to identify (lower
penetrant) genetic factors involved in peripartum cardiomy-
opathy, possibly including factors that underlie geographical
variations in incidence and/or clinical characteristics.
Treatment options
Heart failure in the context of peripartum cardiomyopathy
should be t rea ted accord ing to the guide l ines .
Pharmacological agents such as ACE inhibitors or ARBs are
essential, but due to potential teratogenic consequences they
can only be given after delivery. Beta-blockers have potential
side effects for the neonate as well. Birth weight can be lower
and hypoglycaemia and bradycardia postpartum are de-
scribed. Neonatal monitoring after birth is therefore important.
In case of a left ventricular ejection fraction below 35 %,
anticoagulants should be considered, also because of the hy-
percoagulable state of the peripartum patient. A comprehen-
sive therapeutic algorithm for acute heart failure in peripartum
Fig. 1 Multiple mechanisms lead to the development of PPCM in mice.
Changes in the PGC1α or STAT3 expression lead to aberrant activation of
MnSOD and lead to inadequate antioxidant activity in cardiomyocytes
(red cell). Increased levels of ROS lead to increased cathepsin D (CD)
production. When cathepsin D is secreted into the blood and interacts with
prolactin (PRL) that is secreted by the pituitary gland during pregnancy, it
cleaves PRL to form 16 kDa prolactin. This truncated form of prolactin can
activate the NF-κB pathway in endothelial cells (blue cell) and ultimately
induces transcription of microRNA-146a (miR-146a). Endothelial
exosomes are loaded with miRNA-146a and, following secretion, are
taken up by surrounding cardiomyocytes where it inhibits metabolic
activities via Erbb4, Nras, Notch1, and Irak1. Additionally, MiRNA-
146a inhibits proliferation and promotes cell death in endothelial cells.
Combined with inhibition of vascular endothelial growth factor (VEGF)
by sFLT1 secretion by the placenta, this subsequently leads to angiogenic
imbalance, further deteriorating cardiac function during pregnancy
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cardiomyopathy is given in Fig. 1 in the article by Bachelier-
Walenta et al. [1].
A recent randomised controlled trial found that administra-
tion of bromocriptine has a beneficial effect on NYHA func-
tional class and left ventricular function in patients with peri-
partum cardiomyopathy, which however, needs to be con-
firmed by larger trials as it concerns a relatively small pilot
study[15]. Bromocriptine is a dopamine-2D mimetic that in-
hibits prolactin production. It reduces the stimulating effect of
prolactin on processes such as apoptosis, degeneration of the
cardiac capillary network and vasoconstriction and has previ-
ously been shown to prevent mice from developing peripar-
tum cardiomyopathy.
If a patient is haemodynamically unstable, despite exten-
sive inotropic support, implantation of a left ventricular assist
device should be considered, either as a bridge-to-transplant,
or as a bridge-to-recovery.
Delivery
A spontaneous vaginal delivery is possible in a stable patient,
with pain management to limit large haemodynamic changes
caused by stress. Elective caesarean section carries a slightly
increased risk of thromboembolic or haemorrhagic events and
is associated with larger amounts of blood loss. In case of
haemodynamic instability, the most important treatment for
the mother is ending the pregnancy. This also enables optimal
medical treatment [1, 3].
Prognosis
In contrast to other forms of cardiomyopathy, left ventricular
dysfunction is reversible in a proportion of the patients with
peripartum cardiomyopathy. In 23–54 % of the patients total
recovery of ventricular function occurs, more often in patients
with a more preserved ejection fraction at first presentation
and mainly within 6–12 months. However, recovery can still
be achieved beyond 1 year after first presentation [2, 3].
Possible predictors for poor outcome are a dilated left ventri-
cle, low ejection fraction, low body mass index and low
cholesterol [1].
The reported overall long-term (47–56 months) mortality
varies from 3.3 to 30 % (this tends to be lower in the USA
compared with developing countries such as Haiti and South-
Africa) [2]. Larger prospective and international studies are
needed to be able to accurately estimate mortality and mor-
bidity risks. The recurrence risk of peripartum cardiomyopa-
thy is 30–50 % in subsequent pregnancies [3]. Although
not based on solid data, the current consensus is that
patients should be advised against a new pregnancy if
left ventricular function including diastolic function is
still compromised [2]. Left ventricular dysfunction due to
peripartum cardiomyopathy is associated with a further
decrease of ventricular function and symptoms of heart failure
in every following pregnancy [3].
Peripartum cardiomyopathy registry
To gain further understanding of the prevalence and patho-
physiology of peripartum cardiomyopathy, a registry is need-
ed. Several years ago this was already mentioned by Lok et al.
who proposed a national survey [16]. At the same time the
ESC initiated a working group to carry out a worldwide
survey [11]. In this worldwide survey, data are currently being
collected on possible risk factors, diagnosis, mode of delivery,
standard management and therapeutic interventions currently
performed in each centre for patients presenting with signs
and symptoms of peripartum cardiomyopathy (www.escardio.
org/guidelines-surveys/eorp/surveys/ppcm). The study is
hosted, monitored and financed by the ESC and governed
by the members of the executive committee. The survey is
new and additional to the existing pregnancy registry focusing
on women with structural and ischaemic heart disease
(ROPAC) (www.escardio.org/guidelines-surveys/eorp/
surveys/pregnancy). The Euro Observational Research
Program will allow a comparison of women from around the
world, presenting with peripartum cardiomyopathy and will
report on their 6- and 12-month outcome. In literature, espe-
cially data on peripartum cardiomyopathy fromWestern coun-
tries is lacking. Therefore we would like to encourage
Dutch cardiologists to enter cases in this registry. New
centres volunteering to participate in the study will be
accepted; however, cases can also be reported to the
authors of this manuscript and they will enter the cases
for you. Until now, approximately 180 cases have been
entered into the database. The study will continue until
1000 patients are included.
The only inclusion criteria are: diagnosis of peripartum
cardiomyopathy, signs and symptoms of heart failure and left
ventricular ejection fraction <45 %. Patients can be enrolled
retrospectively up to 6 months after diagnosis.
Conclusions
Peripartum cardiomyopathy can be fatal and occurs at a very
emotional time for (future) parents. Peripartum cardiomyopa-
thy is difficult to diagnose since symptoms of peripartum
cardiomyopathy are to some extent similar to symptoms of a
normal pregnancy. Disease onset and progression are variable
between individuals and several factors have been found to
increase the risk of peripartum cardiomyopathy development.
Moreover, no reliable laboratory tests are currently available
to confirm the diagnosis. Treatment options are limited due to
possible harmful side effects for the foetus. The exact
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mechanism underlying peripartum cardiomyopathy remains
poorly understood, but a cardiac angiogenic imbalance may
play an important role.
As it is difficult to diagnose and geographical incidences
vary greatly, it is imperative to gain further understanding of
disease progression, recurrence risk, and development of treat-
ment options. We encourage Dutch cardiologists to enter
peripartum cardiomyopathy patients into the worldwide preg-
nancy registry in order to get a clearer view of this condition.
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